CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.

CLEARWATER，Fla。-Apyx医疗公司（纳斯达克股票代码：Apyx）（“Apyx医疗；“公司”），专有氦等离子体和射频技术的制造商销售和销售Renuvion®，今天宣布任命Matthew Hill担任首席财务官，自2023年12月4日起生效。

Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023..

Hill先生成功了Tara Semb，该公司于2023年11月9日宣布离职。。

“Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical.

“马特加入我们的执行领导团队，拥有30多年的财务和运营经验，其中20多年一直在医疗行业工作，曾担任四家上市医疗保健公司的首席财务官，”Charlie Goodwin说，Apyx Medical总裁兼首席执行官。

“I’m pleased to welcome Matt to Apyx Medical and look forward to working with him to execute our strategic initiatives and position the Company to deliver strong, sustainable, long-term growth.”.

“我很高兴欢迎Matt来到Apyx Medical，并期待与他合作执行我们的战略举措，并使公司能够实现强劲，可持续，长期的增长。”。

“With its innovative Renuvion technology, large, global market opportunity, recent operational progress and an enhanced balance sheet, I believe Apyx Medical is well-positioned for future success in the cosmetic surgery market,” said Mr. Hill. “I am pleased to join the Company at this exciting time, and look forward to working with Charlie and the rest of the team as we lead Apyx Medical through its next stage of growth and development.”.

希尔先生说：“凭借其创新的创新技术，庞大的全球市场机会，最近的运营进展和增强的资产负债表，我相信Apyx Medical在美容外科市场的未来成功中处于有利地位。”。“我很高兴在这个激动人心的时刻加入该公司，并期待与查理和团队其他成员合作，因为我们领导Apyx Medical进入下一个成长和发展阶段。”。

Mr. Hill joins Apyx Medical from PDS Biotechnology Corporation (Nasdaq: PDSB; “PDS Biotech”), a clinical-stage immunotherapy company, where he served as Chief Financial Officer, leading all aspects of the company’s budgeting, forecasting, financial management and reporting. Prior to joining PDS Biotech, he served as Chief Financial Officer of Strata Skin Sciences (Nasdaq: SSKN), a medical technology company developing, commercializing and marketing products for the treatment of dermatologic conditions, from 2018 to 2021..

Hill先生加入临床阶段免疫治疗公司PDS生物技术公司（纳斯达克股票代码：PDSB；“PDS Biotech”）的Apyx Medical，担任首席财务官，领导公司预算，预测，财务管理和报告的各个方面。在加入PDS Biotech之前，他曾担任Strata皮肤科学（纳斯达克股票代码：SSKN）的首席财务官，该公司是一家医疗技术公司，于2018年至2021年开发，商业化和销售用于治疗皮肤病的产品。。

Prior to joining Strata Skin Sciences, Mr. Hill held CFO roles at several companies, including Velcera, Inc., which developed pet medication for the companion animal health industry, and EP MedSystems, which developed and marketed cardiac electrophysiology products. He was also a Senior Manager at the international accounting and consulting firm, Grant Thornton LLP.

在加入Strata皮肤科学之前，Hill先生在几家公司担任CFO职位，其中包括为伴侣动物健康行业开发pet药物的Velcera公司和开发和销售心脏电生理产品的EP MedSystems公司。他还是Grant Thornton LLP国际会计和咨询公司的高级经理。

Mr. Hill holds a Bachelor of Science in Accounting from Lehigh University..

Hill先生拥有Lehigh大学会计科学学士学位。。

About Apyx Medical Corporation:

关于Apyx医疗公司：

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results.

Apyx Medical Corporation是一家先进的能源技术公司，热衷于通过创新产品提升人们的生活，包括其在美容外科市场销售和销售的氦等离子体技术产品Renuvion®和医院外科市场的J-Plasma®。Renuvion®和J-Plasma®为外科医生提供独特的能力，为组织提供可控的热量，以达到预期的效果。

The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com..

该公司还通过与其他医疗设备制造商的OEM协议，利用其丰富的专业知识和数十年的独特波形经验。有关公司及其产品的更多信息，请参阅Apyx Medical Corporation网站www.ApyxMedical.com。。

Cautionary Statement on Forward-Looking Statements:

关于前瞻性声明的警示性声明：

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved..

本版本中讨论的某些事项以及本公司代表不时发表的口头陈述可能构成1995年“私人证券诉讼改革法”和“联邦证券法”含义范围内的前瞻性陈述。虽然本公司认为此类前瞻性陈述所反映的预期是基于合理的假设，但不能保证其预期会实现。。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S.

除历史事实陈述外的所有陈述均为可被视为前瞻性陈述的陈述，包括但不限于净收入，利润率，支出，净收益，单位净收益或其他财务项目的预测；关于公司可能收到任何政府机构或工具的任何监管批准的预测或假设，包括但不限于美国。

Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance..

食品和药物管理局（“FDA”），供应链中断，组件短缺，制造中断或物流挑战；或宏观经济或地缘政治事务以及这些事项对公司财务业绩的影响。。

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; the impact of the March 14, 2022 FDA Safety Communication on our business and operations; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and the Company’s other filings with the Securities and Exchange Commission.

前瞻性陈述和信息受到某些风险，趋势和不确定性的影响，可能导致实际结果与预期结果大不相同。许多这些因素超出了公司控制或预测的能力。可能导致本公司实际结果出现重大差异并可能影响本公司的重要因素本版本中包含的声明包括但不限于与本公司所属监管环境相关的风险，不确定性和假设，包括公司能够在国内和国际上获得FDA和其他政府和监管机构对其产品的必要批准；2022年3月14日FDA安全沟通对我们业务和运营的影响；商品价格和可用性突然或极端波动，包括供应链中断；一般经济，商业或人口状况或趋势的变化；地缘政治环境的变化和影响；本公司因未决或受威胁的诉讼，索赔，争议或调查可能产生的责任和费用；以及本公司截至2022年12月31日止财政年度10-K年度报告中描述的其他风险以及本公司与证券交易委员会的其他文件。

For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise..

对于本版本中的前瞻性声明，本公司要求保护安全港，以获得1995年“私人证券诉讼改革法”中包含的前瞻性声明。无论是由于新信息，未来事件还是其他原因，本公司均无义务更新或补充任何前瞻性声明。。